Your browser is no longer supported. Please, upgrade your browser.
ContraFect Corporation
Index- P/E- EPS (ttm)-1.48 Insider Own7.91% Shs Outstand27.85M Perf Week-3.92%
Market Cap138.33M Forward P/E- EPS next Y-0.97 Insider Trans0.00% Shs Float24.70M Perf Month-6.84%
Income-28.20M PEG- EPS next Q-0.22 Inst Own46.40% Short Float21.13% Perf Quarter-42.68%
Sales- P/S- EPS this Y19.90% Inst Trans0.04% Short Ratio4.28 Perf Half Y-30.70%
Book/sh0.45 P/B8.18 EPS next Y11.00% ROA-54.90% Target Price- Perf Year-40.16%
Cash/sh1.13 P/C3.25 EPS next 5Y12.70% ROE-209.00% 52W Range3.55 - 8.00 Perf YTD-27.13%
Dividend- P/FCF- EPS past 5Y35.10% ROI- 52W High-55.50% Beta0.94
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low0.28% ATR0.26
Employees33 Current Ratio7.70 Sales Q/Q- Oper. Margin- RSI (14)34.91 Volatility6.35% 6.71%
OptionableYes Debt/Eq0.00 EPS Q/Q81.50% Profit Margin- Rel Volume0.37 Prev Close3.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.22M Price3.56
Recom2.00 SMA20-11.19% SMA50-21.74% SMA200-31.71% Volume182,303 Change-3.26%
Jun-09-20Initiated Mizuho Buy $12
Jun-09-20Initiated Cantor Fitzgerald Overweight $15
Jul-28-16Initiated Piper Jaffray Overweight
Jul-22-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Maxim Group Buy $8 → $7
Dec-31-15Reiterated Maxim Group Buy $16 → $9
May-03-21 07:30AM  
Apr-26-21 07:30AM  
Apr-15-21 06:30PM  
Apr-09-21 06:40AM  
Mar-30-21 07:30AM  
Mar-22-21 04:05PM  
Mar-17-21 04:01PM  
Mar-16-21 06:27AM  
Mar-12-21 07:36AM  
Mar-11-21 04:05PM  
Feb-11-21 07:00AM  
Dec-30-20 12:55AM  
Dec-11-20 05:59PM  
Nov-24-20 06:56AM  
Nov-13-20 08:33AM  
Oct-31-20 08:00AM  
Oct-26-20 07:00AM  
Oct-01-20 07:31AM  
Sep-09-20 07:30AM  
Aug-25-20 07:30AM  
Aug-19-20 05:50AM  
Aug-14-20 07:30AM  
Jul-20-20 07:30AM  
Jul-03-20 08:48AM  
Jun-18-20 10:56AM  
Jun-17-20 07:30AM  
Jun-15-20 07:30AM  
Jun-10-20 01:46PM  
May-29-20 06:43AM  
May-26-20 07:30AM  
May-22-20 07:10AM  
May-21-20 10:59PM  
May-15-20 07:30AM  
May-11-20 07:30AM  
Apr-21-20 07:00AM  
Mar-30-20 05:00AM  
Mar-23-20 06:15AM  
Mar-21-20 09:01AM  
Mar-18-20 07:00AM  
Mar-04-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 03:45PM  
Feb-04-20 07:00AM  
Feb-03-20 07:00AM  
Jan-27-20 07:00AM  
Jan-22-20 07:00AM  
Jan-21-20 05:00AM  
Jan-13-20 08:00AM  
Jan-10-20 07:00AM  
Jan-06-20 05:30PM  
Jan-04-20 07:30AM  
Dec-20-19 10:56AM  
Dec-18-19 07:00AM  
Dec-17-19 09:25AM  
Dec-16-19 07:30AM  
Dec-10-19 08:46AM  
Dec-09-19 04:03PM  
Nov-29-19 09:00AM  
Nov-18-19 08:05AM  
Nov-12-19 07:00AM  
Nov-05-19 07:00AM  
Oct-07-19 09:05AM  
Oct-02-19 07:00AM  
Oct-01-19 05:29PM  
Sep-26-19 07:00AM  
Sep-04-19 05:07PM  
Aug-28-19 07:00AM  
Aug-16-19 10:45AM  
Aug-09-19 07:00AM  
Jul-01-19 09:13AM  
Jun-20-19 11:13AM  
Jun-19-19 01:08PM  
Jun-17-19 05:00PM  
Jun-07-19 09:27AM  
Jun-06-19 07:00AM  
Jun-03-19 07:00AM  
May-31-19 07:00AM  
May-20-19 10:15AM  
May-10-19 07:19AM  
May-08-19 07:00AM  
Apr-30-19 10:30AM  
Apr-16-19 05:15AM  
Apr-13-19 09:38AM  
Apr-12-19 10:08AM  
Apr-08-19 07:00AM  
Apr-04-19 07:00AM  
Apr-02-19 07:00AM  
Mar-21-19 07:00AM  
Mar-20-19 10:30AM  
Mar-14-19 08:01AM  
Mar-13-19 07:00AM  
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.